Ultime notizie per Bausch & Lomb (NYSE:BLCO) Azioni

Bausch & Lomb

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb Corp

UBS analyst Peter Grom maintains JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) with a Buy and lowers the price target from $134 to $129.

News

Price Target

Analyst Ratings

UBS Maintains Buy on JM Smucker, Lowers Price Target to $129

ICE is currently in its 8th Phase of the 18-Phase Adhishthana Cycle. While the structure appears strong and suggests a potential breakout, a pullback may occur before that breakout takes place. Here&#8217;s a breakdown of the setup and why a delay is more likely to occur.
<h3 class="wp-block-heading">ICE So Far: Strong Alignment with Adhishthana Principles</h3>
ICE has demonstrated a 90% alignment with the Adhishthana Principles, our proprietary framework that forecasts stock behavior through cyclical analysis, incorporating both quantitative signals and behavioral archetypes.
Some of its strongest and clearest alignments have come in Phases 3, 6, and 7:
<h4 class="wp-block-heading">Phase 3: The Yajya Formation</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="616" height="538" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132539/ICE-Phase-3-Adhishthana.png" alt="Fig.1 ICE Phase 3 (Source: Adhishthana.com)" class="wp-image-14024" style="width:445px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132539/ICE-Phase-3-Adhishthana.png 616w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132539/ICE-Phase-3-Adhishthana-300x262.png 300w" sizes="(max-width: 616px) 100vw, 616px" /><figcaption class="wp-element-caption">Fig.1 Phase 3 (Source: Adhishthana.com)</figcaption></figure>
In Phase 3, ICE rallied briefly, formed an arc, and then dropped sharply — a textbook example of the Yajya Formation. The decline of approximately 33% confirmed the pattern's integrity.
<h4 class="wp-block-heading">Phase 6: The Level of Nirvana</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1082" height="706" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132612/ICE-Phase-6-Adhishthana.png" alt="Fig.2 ICE Phase 6 (Source: Adhishthana.com)" class="wp-image-14025" style="width:671px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132612/ICE-Phase-6-Adhishthana.png 1082w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132612/ICE-Phase-6-Adhishthana-300x196.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132612/ICE-Phase-6-Adhishthana-1024x668.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132612/ICE-Phase-6-Adhishthana-768x501.png 768w" sizes="(max-width: 1082px) 100vw, 1082px" /><figcaption class="wp-element-caption">Fig.2 Phase 6 (Source: Adhishthana.com)</figcaption></figure>
After 24 bars of trading, ICE established its Nirvana Level at 122.46. This level now acts as a key valuation barometer throughout the cycle and serves as a gravitational level for any future selling pressure.
<h4 class="wp-block-heading">Phase 7: The Fall of Artha and Artharthi</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="772" height="472" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132651/ICE-Phase-7-Adhishthana.png" alt="Fig.3 ICE Phase 7 (Source: Adhishthana.com)" class="wp-image-14026" style="width:523px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132651/ICE-Phase-7-Adhishthana.png 772w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132651/ICE-Phase-7-Adhishthana-300x183.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06132651/ICE-Phase-7-Adhishthana-768x470.png 768w" sizes="(max-width: 772px) 100vw, 772px" /><figcaption class="wp-element-caption">Fig.3 Phase 7 (Source: Adhishthana.com)</figcaption></figure>
In Phase 7, ICE followed the Adhishthana expectation almost perfectly, it dropped roughly 15% and formed exactly seven red bars before beginning to recover, consistent with Phase 7 behavior.
<h3 class="wp-block-heading">Why a Breakout May Be Delayed</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="539" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06133226/ICE-Cakra-Structure-Adhishthana.png" alt="Fig.4 ICE Adhishthana Cakra Structure (Source: Adhishthana.com)" class="wp-image-14027" style="width:641px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06133226/ICE-Cakra-Structure-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06133226/ICE-Cakra-Structure-Adhishthana-300x135.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06133226/ICE-Cakra-Structure-Adhishthana-1024x460.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06133226/ICE-Cakra-Structure-Adhishthana-768x345.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.4 Adhishthana Cakra Structure (Source: Adhishthana.com)</figcaption></figure>
Despite the bullish setup, ICE is currently in Phase 8, a stage where stocks typically complete the Cakra, a curved, often bullish channel that spans from Phases 4 through 8.
Right now, ICE is near the upper end of its Cakra, and continuing higher from here would indicate that it is breaking above the Cakra before the optimal time. According to the principles, such a breakout should happen in Phase 9, which starts on 6 October 2025.
Note: For more on this, read my Benzinga article where I break down CrowdStrike's structure and discuss the risks of a premature breakout: <a href="https://www.benzinga.com/markets/equities/25/06/45789662/crowdstrike-why-investors-should-stay-cautious">CrowdStrike: Why Investors Should Stay Cautious</a>
<h3 class="wp-block-heading">Outlook and Investor Takeaway</h3>
Given the high alignment ICE has shown with Adhishthana Principles, it is more likely that the stock will retest the lower end of the Cakra, around the $160-150 level, before a meaningful breakout can occur in Phase 9.
<ul class="wp-block-list">
<li>Existing Longs: Consider hedging your positions in the short term. </li>
<li>Potential Buyers: Patience is the key &#8211; wait for a potential pullback near $160-150 to enter and ride the Phase 9 breakout. </li>
<li>It is also advisable to monitor the Cakra closely, as a breakdown from it could trigger a deep and prolonged bearish move.</li>
</ul>

Equities

Technicals

Opinion

Signals

Trading Ideas

ICE Stock: Bullish Setup But A Pullback Is Likely

UBS analyst Jay Sole maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Buy and lowers the price target from $150 to $146.

UBS Maintains Buy on PVH, Lowers Price Target to $146

FuelCell Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares traded higher Friday morning after the company announced in a press release mixed results for the <a href="https://www.benzinga.com/pressreleases/25/06/g45810903/fuelcell-energy-reports-second-quarter-of-fiscal-2025-results" target="_blank" rel="noreferrer noopener">second quarter of fiscal 2025</a>.
Revenue grew 67% year over year to $37.41 million, beating the consensus estimate of $32.41 million.
Product revenue rose to $13 million from zero a year ago, reflecting increased sales activity. Service revenue jumped to $8.1 million, driven by module replacements under a United Illuminating contract.
Generation revenue declined to $12.1 million from $14.1 million due to maintenance downtime, while Advanced Technologies revenue fell to $4.1 million from $6.9 million, impacted by lower contributions from Exxon Mobil-related and government contracts.
Gross loss widened to $9.4 million from $7.1 million a year ago, primarily due to lower margins on tech and service contracts. The impact was partially offset by reduced costs related to the Toyota Project.
Net loss per share narrowed to $1.79 from $2.18, benefiting from a higher share count and income from non-controlling interest. The result missed the consensus loss estimate of $1.43.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45808780/fuelcell-energy-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call" rel="noreferrer noopener">FuelCell Energy Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
Operating expenses fell to $26.4 million from $34.3 million, driven by reductions in R&amp;D spending and compensation expenses.
As of April 30, 2025, the company held $240 million in cash, restricted cash and short-term investments, down from $318 million on Oct. 31, 2024. This included $116.1 million in unrestricted cash, $60.9 million in short-term investments and $63.1 million in restricted cash.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45679693/plug-powers-record-hydrogen-output-in-georgia-signals-growth-potential" rel="noreferrer noopener">Plug Power&#8217;s Record Hydrogen Output In Georgia Signals Growth Potential</a>
The company raised $7.7 million in net proceeds during the quarter by selling approximately 1.6 million shares at an average price of $5.00 each.
Backlog grew 18.7% year over year to $1.26 billion, driven by a long-term service agreement with Gyeonggi Green Energy and a 20-year, 7.4 MW power purchase agreement in Hartford, Connecticut.
FuelCell Energy announced a new global restructuring plan on June 5, cutting its workforce by 22% and reducing global headcount to about 426 employees. The move follows a November 2024 plan that aimed to cut costs by 15% and included a 13% staff reduction.
The latest restructuring focuses on lowering overhead, deferring certain compensation, pausing most solid oxide development, and aligning production at the Torrington, Connecticut, facility with contracted demand. As of April 30, 2025, the plant was operating at an annualized rate of 31 MW, with near-term output expected to decline under the new plan. The company targets positive adjusted EBITDA once the facility scales to 100 MW annually.
&#8220;Today we are reiterating our focused strategy that prioritizes advancement of our carbonate platform with the goal of meeting accelerating market demand driven by AI data centers, our distributed power generation solutions, and our carbon recovery and utilization applications,&#8221; said President and CEO Jason Few.
Few added that the restructuring will streamline operations in the U.S., Canada, and Germany, sharpen focus on core technologies, and improve profitability. He cited increased policy support for natural gas as a catalyst for broader adoption of FuelCell&#8217;s carbonate platform, which already operates using natural gas and biofuels.
&#8220;We believe these actions — cutting our workforce, reducing SG&amp;A and focusing on commercially available technology — will help shorten our path to profitability while preserving long-term innovation in electrolysis and carbon capture,&#8221; Few said.
&#8220;Our priorities remain clear: reduce discretionary spending, decrease cash burn, and accelerate our trajectory toward sustained, positive adjusted EBITDA,&#8221; said Michael Bishop, executive vice president, CFO and treasurer. &#8220;In parallel, we are actively pursuing strategic financing to support commercial execution, including our Korea repowering project, where we successfully delivered four modules this quarter.&#8221;
FCEL Price Action: FuelCell Energy shares are trading higher by 30.58% at $6.74 on Friday at publication.
Read Next: 
 • <a href="https://www.benzinga.com/markets/economic-data/25/06/45812372/us-labor-markets-defies-tariff-concerns-as-nonfarm-payrolls-wages-top-expectations-in-may" target="_blank" rel="noreferrer noopener">U.S. Labor Markets Defies Tariff Concerns As Nonfarm Payrolls, Wages Top Expectations In May</a>
Photo: Courtesy FuelCell Energy

Earnings

Movers

FCEL

FuelCell Energy Stock Soars After Mixed Q2 Results: Targets Profitability With Scaled-Back Ops, Renewed Tech Focus

WIIM

SRPT

Sarepta Therapeutics shares are trading higher after Scotiabank upgraded the stock from Sector Perform to Sector Outperform.

Goldman Sachs analyst Ati Modak upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Neutral to Buy and raises the price target from $156 to $195.

Upgrades

Goldman Sachs Upgrades MasTec to Buy, Raises Price Target to $195

UBS analyst Jay Sole maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $290.

LULU

UBS Maintains Neutral on Lululemon Athletica, Lowers Price Target to $290

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return of 13.27%. Currently, F5 has a market capitalization of $17.06 billion. 
Buying $100 In FFIV: If an investor had bought $100 of FFIV stock 20 years ago, it would be worth $1,165.01 today based on a price of $294.51 for FFIV at the time of writing.
<h3>F5's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749220217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIV

Here's How Much You Would Have Made Owning F5 Stock In The Last 20 Years

Rumors

IPOs

OMDA

Omada Health IPO Indicating $25.07/Share On 190K Shares; IPO Priced At $19/Share

Omada Health IPO Indicating $30.25/Share On 170k Shares; IPO Priced At $19/Share

BTIG analyst Janine Stichter maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $420 to $405.

BTIG Maintains Buy on Lululemon Athletica, Lowers Price Target to $405

Bernstein analyst Peter Weed downgrades CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Outperform to Market Perform and maintains the price target from $371 to $371.

Downgrades

CRWD

Bernstein Downgrades CrowdStrike Holdings to Market Perform, Maintains Price Target to $371

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Loop Capital analyst Alton Stump downgraded the rating for McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Buy to Hold and lowered the price target from $346 to $315. McDonald&#8217;s shares closed at $308.98 on Thursday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Eric Wolfe downgraded American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) from Buy to Neutral and maintained the price target of $41. American Homes 4 Rent shares closed at $36.87 on Thursday. <a href="https://www.benzinga.com/quote/AMH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MCD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MCD/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-1024x598.png" alt="" class="wp-image-941250" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

This McDonald's Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday

Walt Disney Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) <a href="https://www.benzinga.com/topic/walt-disney-world" target="_blank" rel="noreferrer noopener">domestic theme parks</a> have been the growth engine for tourism, job creation, and tax revenue.
Disney Parks &amp; Resorts generated a historic $67 billion annual economic impact from coast to coast. And they support over 403,000 direct and indirect jobs, not just in California and Florida, but <a href="https://thewaltdisneycompany.com/disney-parks-economic-impact/" target="_blank" rel="noreferrer noopener">all 50 states</a>.
According to Tourism Economics, an Oxford Economics company, Disneyland Resort in Anaheim, California, generates $16.1 billion in annual economic impact across Southern California and supports more than 102,000 jobs in the region.
Also Read: <a href="https://www.benzinga.com/25/05/45266716/disneys-streaming-gains-park-strength-cash-surge-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">Disney&#8217;s Streaming Gains, Park Strength, Cash Flow Drive Analyst Optimism</a>
The company&#8217;s plan to &#8216;turbocharge&#8217; the growth of Disney&#8217;s domestic parks will increase capital expenditures in the U.S. to $30 billion through 2033. The plans include:
<ul class="wp-block-list">
<li>Expanding the Magic Kingdom</li>
<li>Creating a new Tropical Americas land in Disney&#8217;s Animal Kingdom</li>
<li>Launching a land based on Pixar Animation Studios&#8217; Monsters, Inc at Disney&#8217;s Hollywood Studios</li>
<li>Doubling the size of Avengers Campus at Disney&#8217;s California Adventure park.</li>
</ul>
Walt Disney reported <a href="https://www.benzinga.com/25/05/45251203/disney-rides-strong-subscriber-growth-and-movie-hits-lifts-forecast-with-1-billion-streaming-goal" target="_blank" rel="noreferrer noopener">fiscal second-quarter 2025</a> revenue growth of 7% to $23.62 billion. It beat the analyst consensus of $23.14 billion driven by its Entertainment and Experiences businesses. Adjusted EPS of $1.45 beat the analyst consensus of $1.20.
Disney&#8217;s experiences division benefited from visitors to parks in California and Florida, holiday package sales, and the launch of the Disney Treasure ship in December.
Disney and Miral, a creator of immersive destinations and experiences, announced a deal to build a theme park resort on Yas Island in Abu Dhabi, United Arab Emirates.
For fiscal 2025, Disney projected an adjusted EPS&nbsp;of $5.75, an increase of 16% over fiscal 2024 versus a $5.44 analyst estimate (compared to the prior estimate of high-single-digit&nbsp;growth).
Price Actions: DIS stock is up 1.23% at $113.90 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/05/45692478/disney-adds-fan-perks-to-win-over-us-viewers-in-streaming-battle" target="_blank" rel="noreferrer noopener">Disney Adds Fan Perks To Win Over US Viewers In Streaming Battle</a></li>
</ul>
Image: Shutterstock

Disney Parks Drive $67 Billion In US Economic Impact, Support Over 400K Jobs Nationwide

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday.
Shares of Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) rose sharply during Friday's session after the company reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/NX">financial results</a>.
Quanex Building reported quarterly earnings of 60 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $452.50 million which beat the analyst consensus estimate of $439.30 million.
Quanex Building Products shares jumped 23.4% to $21.10 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Tango Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares jumped 27% to $4.4776.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) jumped 17.7% to $97.48 after gaining 168% on Thursday.</li>
<li>The Generation Essentials Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGE#NYSE">TGE</a>) rose 17% to $11.76.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) gained 15.2% to $15.94 after the company reported better-than-expected third-quarter sales results.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) rose 15.8% to $8.48.</li>
<li>Taseko Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGB#NYSE">TGB</a>) gained 13.5% to $2.9450.</li>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) surged 13.2% to $6.78.</li>
<li>Byrna Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) rose 12.7% to $29.96. Byrna Technologies announced preliminary fiscal second quarter record revenues of $28.5 million.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) rose 11.7% to $18.74. Wolfe Research analyst Trevor Allinson initiated coverage on QXO with an Outperform rating and announced a price target of $44.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) gained 10% to $18.70.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) climbed 9.8% to $14.05.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 9.3% to $34.42.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) climbed 9.1% to $147.34.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) rose 8.2% to $17.78.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7.7% to $689.00.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) gained 6.6% to $198.94. AeroVironment will report its financial results for the fourth quarter after the market closes on Tuesday, June 24.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

APLD

AVAV

BYRN

COGT

CRCL

CRWV

LEGN

MANU

QBTS

RCAT

TNGX

TSSI

Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) <a href="https://www.benzinga.com/pressreleases/25/06/g45810251/arvinas-announces-submission-of-new-drug-application-to-u-s-fda-for-vepdegestrant-for-patients-wit" target="_blank" rel="noreferrer noopener">with its partner</a> Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">endocrine-based therapy</a>.
This submission is based on Phase 3 VERITAC-2 trial results evaluating vepdegestrant versus fulvestrant.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651990/arvinas-touts-positive-data-from-potential-parkinsons-candidate-in-human-study-with-healthy-volunteers" rel="noreferrer noopener">Arvinas Potential Parkinson&#8217;s Treatment Shows Positive Data In Human Study</a>
At the American Society of Clinical Oncology, the companies shared detailed results from the Phase 3 VERITAC-2 trial.
These detailed results follow the March 2025 announcement of the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44255339/arvinas-pfizer-breast-cancer-drug-fails-to-show-progression-free-survival-benefit-in-trial" rel="noreferrer noopener">topline results from VERITAC-2</a>.
In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among patients with an estrogen receptor 1 (ESR1) mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant.
The median PFS was 5 months with vepdegestrant <a href="https://www.benzinga.com/pressreleases/25/05/g45709824/arvinas-and-pfizers-vepdegestrant-significantly-improves-progression-free-survival-for-patients-wi" target="_blank" rel="noreferrer noopener">versus 2.1 months with fulvestrant</a>.
The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.
Vepdegestrant was generally well tolerated in the trial, with a safety profile consistent with that observed in previous studies, and mostly low-grade treatment-emergent adverse events (TEAEs).
Overall survival (OS), the key secondary endpoint in VERITAC-2, was immature at the time of the analysis, with less than a quarter of the required number of events having occurred.
Additional secondary endpoints include clinical benefit rate (CBR), objective response rate (ORR), and duration of response.
In patients with an ESR1 mutation, CBR was 42.1% with vepdegestrant versus 20.2% with fulvestrant, and ORR was 18.6% with vepdegestrant versus 4.0% with fulvestrant.
The median duration of response was not reached.
ARVN, PFE Price Action: ARVN stock is up 4.91% at $7.26, and Pfizer stock is up 1.79% at $23.25 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/sports/25/06/45812523/manchester-united-stock-jumps-after-q3-profit-turnaround-matchday-growth-and-stadium-plans" target="_blank" rel="noreferrer noopener">Manchester United Stock Jumps After Q3 Profit Turnaround, Matchday Growth, And Stadium Plans</a></li>
</ul>
Photo: jittawit21 via Shutterstock

Biotech

Health Care

General

ARVN

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

<a href="https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/">https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/</a>

PHGE

'Wall Street Sees 3,000% Upside as This $13M Biotech Tackles Medicine's Superbug Crisis (PHGE)'- The Finance Herald

UBS analyst Peter Grom maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Sell and lowers the price target from $54 to $52.

UBS Maintains Sell on General Mills, Lowers Price Target to $52

Investors have followed Michael Burry's trades ever since he predicted the financial crisis of 2008 and profited from it by taking up short positions. The man still known to many as "The Big Short" investor is making headlines for his bearish outlook on one of the world's biggest tech stocks. Benzinga examines why Burry has taken short positions on Nvidia (NASDAQ:<a href="https://www.benzinga.com/quote/NVDA"> NVDA</a>).
<a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45632498/nvidias-40-billion-oracle-win-may-trigger-a-chip-etf-rally">Nvidia</a> shares have spent much of the last 18 months on a bull run powered by AI's emergence as the world's hottest investment sector. As recently as May 2023, Nvidia shares were trading in the $35 range. Then it became clear that Nvidia's graphics processors and chipsets were mission-critical components in AI development, and the company's stock was off to the races.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Nvidia shares increased from around $40 in January 2024 to $147.16 by early November. The company's market cap grew to an astonishing $3 trillion, and CEO Jensen Huang achieved near celebrity status as his company gate-crashed the S&amp;P 500 Magnificent Seven. That kind of explosion in share price and market cap made Nvidia one of the biggest stories of 2024, but Burry knows what goes up must come down.
<a href="https://www.barchart.com/story/news/32563704/michael-burry-is-betting-against-nvidia-stock-should-you-follow-the-big-short-star-and-sell-nvda-now">Barchart</a> is reporting that Burry's Scion Asset Management has numerous put options in Nvidia. Beyond that, the water gets a little murky in terms of predicting Burry's long game. Barchart compiled the option data from Scion's March 13F filings, but those filings include multiple shorts. Scion is also betting against Alibaba (NYSE:<a href="https://www.benzinga.com/quote/BABA"> BABA</a>), Baidu, and Tripadvisor.com (NASDAQ:<a href="https://www.benzinga.com/topic/tripadvisor"> TRIP</a>). The filings only note that the combined total of Scion's shorts is $199 million.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
There is no information about expiration dates or strike prices, and the filings don't disclose whether Scion has long positions on Nvidia or the other stocks it's shorting. All this makes it difficult to decipher whether Burry has completely soured on Nvidia. President Donald Trump's tariffs have rattled multiple economic sectors, especially tech and retail, where Nvidia and<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45620670/alibaba-eyes-growth-in-other-markets-as-us-ties-strained-says-chairman"> Alibaba</a> operate.
Like many tech companies, Nvidia is heavily dependent on Chinese components, and jitters over the tariffs saw its shares slump to the $90 range in late March. Trump is still negotiating with China, and Nvidia has rebounded to $135.50 per share. The next shoe to drop will be quarterly earnings, which Burry may be expecting to fall short of projections.&nbsp;
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
So, the pressing question for investors is whether Burry is simply hedging with these short bets or believes Nvidia is overpriced and due for a correction. He has a proven knack for getting out of high-performing positions before the bottom drops, and these shorts could be part of that trend. However, the fact that Burry and Scion have $199 million in shorts spread across multiple positions may indicate that Burry is guarding against the downside.
With that said, Burry shorting Nvidia should give investors cause to assess their long-term positions and goals with this stock. In the meantime, keep your eyes peeled for Nvidia's earnings report and news on the tariff negotiations. Both of those will have a significant impact on Burry's next moves with Nvidia.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

Is The Bull Run Over For Nvidia– 'The Big Short' Investor Michael Burry Taking Up Short Positions

Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) today announced the expansion of its Capa&#xAE; caprolactone distribution network by establishing Jamplast as its exclusive distributor for Capa TP for bioplastics in the United States and Canada.
Jamplast, a leading plastic resin distributor of biopolymers, engineering polymers and commodity grade thermoplastics serving plastic processing manufacturers, will leverage the company's technical sales and marketing networks in North America to maximize the sales of Ingevity's Capa caprolactone products.
Ingevity's agreement with Jamplast is effective as of April 23, 2025.

NGVT

Ingevity Expands Capa Caprolactone Distribution Network By Establishing Jamplast As Exclusive Distributor For Capa TP For Bioplastics In US And Canada

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

Legal

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

Comments

Bausch & Lomb

Notizie

Ultime notizie per Bausch & Lomb (NYSE:BLCO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO